Absci Corporation (ABSI)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
2.86
0.15 (5.54%)
At close: Jan 15, 2025, 3:59 PM
2.85
-0.35%
After-hours Jan 15, 2025, 04:57 PM EST
Company Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.
Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.
Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation
Country | United States |
IPO Date | Jul 22, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 155 |
CEO | Sean McClain |
Contact Details
Address: 18105 SE Mill Plain Boulevard Vancouver, Washington United States | |
Website | https://www.absci.com |
Stock Details
Ticker Symbol | ABSI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001672688 |
CUSIP Number | 00091E109 |
ISIN Number | US00091E1091 |
Employer ID | 45-3931977 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Sean McClain | Founder, Chief Executive Officer, President & Director |
Dr. Zachariah Jonasson Ph.D. | Chief Business Officer & Chief Financial Officer |
Karin Wierinck | Chief People Officer |
Shelby Walker J.D. | Chief Legal Officer |
Alexander Khan CPA | Vice President of Finance & Head of Investor Relations |
Dr. Andreas Busch Ph.D. | Chief Innovation Officer & Member of Scientific Advisory Board |
Jens Plassmeier Ph.D. | Senior Vice President of Synthetic Biology R&D |
Melissa Patterson Ph.D. | Chief of Staff |
Todd Bedrick CPA | Senior Vice President & Chief Accounting Officer |
Wen Sha | Chief of Staff |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | SCHEDULE 13G | Filing |
Dec 09, 2024 | 4 | Filing |
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | 8-K | Current Report |
Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Oct 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Oct 16, 2024 | 4 | Filing |
Oct 16, 2024 | 4 | Filing |
Oct 16, 2024 | 4 | Filing |